GlassScriptPhysician profile
Stephen Kimmel
NPI 1134120595
$12,170.10
in general payments reported to CMS, 2019-2025
39 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,292 · 2020: $1,090 · 2021: $1,290 · 2022: $1,963 · 2023: $2,257 · 2024: $2,434 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,192 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,191.69 |
| Education | $343.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,036.19 | 2019-2025 | |
| Janssen Biotech, INC. | $1,184.17 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $1,141.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,013.14 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $951.30 | 2019-2025 | |
| Ucb, INC. | $843.87 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $749.38 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $601.13 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $578.38 | 2022-2025 | Sotyktu |
| Pfizer INC. | $445.13 | 2019-2025 | |
| Lilly USA, LLC | $403.18 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $331.01 | 2021-2024 | Adbry |
| Incyte Corporation | $274.03 | 2022-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $265.23 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $244.55 | 2019-2024 | Cabtreo, Jublia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $133.70 | 2020-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $131.17 | 2023-2024 | Vtama |
| Kerecis Limited | $101.03 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Tactile Systems Technology INC | $78.25 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Mayne Pharma Commercial LLC | $73.42 | 2019-2022 | |
| Organon LLC | $64.75 | 2024-2025 | Vtama |
| Almirall LLC | $54.43 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $52.86 | 2020 | |
| Organogenesis INC. | $49.02 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.24 | 2023-2024 | Cyltezo |
| Hill Dermaceuticals, INC. | $40.01 | 2020-2021 | |
| Epi Health, LLC | $39.44 | 2019-2021 | |
| Genentech USA, INC. | $30.90 | 2019 | |
| Dermira, INC. | $27.42 | 2019 | |
| Vyne Pharmaceuticals INC. | $26.29 | 2021 | |
| Smith+Nephew, INC. | $26.06 | 2021-2023 | Grafix Pl |
| Journey Medical Corporation | $24.53 | 2020-2022 | |
| Promius Pharma LLC | $21.48 | 2019 | |
| Biofrontera INC. | $17.10 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.35 | 2025 | Nuzyra |
| Celgene Corporation | $16.08 | 2019 | |
| Nabriva Therapeutics, Plc | $14.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2022 | |
| Mission Pharmacal Company | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kimmel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.